Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.

Overgaard RV, Petri KC, Jacobsen LV, Jensen CB

Clinical pharmacokinetics1 Nov 2016Cited by 44 (Europe PMC)

PMID27193270PMCIDPMC5069304DOI10.1007/s40262-016-0410-7PepBankPUB-27193270

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialPharmacokinetics
In obese and overweight adults, liraglutide exposure was dose-proportional up to and including 3.0 mg.
In plain wordsIn overweight and obese adults, the amount of liraglutide in the blood rose in proportion to the dose, up to 3.0 mg.
Peptide
Liraglutide
Outcome
Not applicableDose proportionality of exposure
Study
n = 331
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
up to and including 3.0 mgAs given in this study (human).
Source sentences
Summary
Dose-proportional exposure of liraglutide up to and including 3.0 mg was confirmed.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327001
02HumanObservational studyPharmacokinetics
In adults with overweight or obesity, liraglutide 3.0 mg exposure was lower in heavier subjects and higher in lighter subjects than in a 100 kg reference subject.
In plain wordsIn overweight and obese adults, heavier people had lower liraglutide levels and lighter people had higher levels at the same dose.
Peptide
Liraglutide
Outcome
MixedExposure by body weight
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Measurements
Exposure difference versus 100 kg reference
44%
234 kg, lower
Exposure difference versus 100 kg reference
41%
60 kg, higher
Source sentences
Summary
Compared with a reference subject weighing 100 kg, exposure of liraglutide 3.0 mg was 44 % lower for a subject weighing 234 kg (90 % CI 41-47), 41 % higher for a subject weighing 60 kg (90 % CI 37-46), and 32 % higher (90 % CI 28-35) in females than males with the same body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327002
03HumanObservational studyPharmacokinetics
In adults with overweight or obesity, liraglutide 3.0 mg exposure was higher in females than in males with the same body weight.
In plain wordsIn overweight and obese adults, women had higher liraglutide levels than men of the same weight.
Peptide
Liraglutide
Outcome
IncreaseExposure by sex
Study
n: not reported in source
Comparator
Males of the same body weight
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Measurements
Exposure difference, females versus males
32%
same body weight, higher
Source sentences
Summary
Compared with a reference subject weighing 100 kg, exposure of liraglutide 3.0 mg was 44 % lower for a subject weighing 234 kg (90 % CI 41-47), 41 % higher for a subject weighing 60 kg (90 % CI 37-46), and 32 % higher (90 % CI 28-35) in females than males with the same body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327003
04HumanObservational studyPharmacokinetics
In adults with overweight or obesity, age of 70 years or older did not influence liraglutide 3.0 mg exposure.
In plain wordsIn overweight and obese adults, being 70 or older did not change liraglutide levels.
Peptide
Liraglutide
Outcome
No significant changeEffect of age 70 years or older on exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
while age ≥70 years, race, ethnicity and baseline glycaemic status did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327004
05HumanObservational studyPharmacokinetics
In adults with overweight or obesity, race did not influence liraglutide 3.0 mg exposure.
In plain wordsIn overweight and obese adults, race did not change liraglutide levels.
Peptide
Liraglutide
Outcome
No significant changeEffect of race on exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
while age ≥70 years, race, ethnicity and baseline glycaemic status did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327005
06HumanObservational studyPharmacokinetics
In adults with overweight or obesity, ethnicity did not influence liraglutide 3.0 mg exposure.
In plain wordsIn overweight and obese adults, ethnicity did not change liraglutide levels.
Peptide
Liraglutide
Outcome
No significant changeEffect of ethnicity on exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
while age ≥70 years, race, ethnicity and baseline glycaemic status did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327006
07HumanObservational studyPharmacokinetics
In adults with overweight or obesity, baseline glycaemic status did not influence liraglutide 3.0 mg exposure.
In plain wordsIn overweight and obese adults, starting blood sugar status did not change liraglutide levels.
Peptide
Liraglutide
Outcome
No significant changeEffect of baseline glycaemic status on exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
while age ≥70 years, race, ethnicity and baseline glycaemic status did not.
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327007
08HumanObservational studyPharmacokinetics
In a post hoc analysis, injection site did not significantly influence liraglutide 3.0 mg exposure.
In plain wordsIn a further analysis, the injection site did not change liraglutide levels in a meaningful way.
Peptide
Liraglutide
Outcome
No significant changeEffect of injection site on exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
Neither injection site nor renal function significantly influenced exposure of liraglutide 3.0 mg (post hoc analysis).
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327008
09HumanObservational studyPharmacokinetics
In a post hoc analysis, renal function did not significantly influence liraglutide 3.0 mg exposure.
In plain wordsIn a further analysis, kidney function did not change liraglutide levels in a meaningful way.
Peptide
Liraglutide
Outcome
No significant changeEffect of renal function on exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
Neither injection site nor renal function significantly influenced exposure of liraglutide 3.0 mg (post hoc analysis).
2 context sentences(design, population, supporting numbers)
Summary · context
Samples for pharmacokinetic analysis were drawn at weeks 2, 12 and 28 of the phase IIIa SCALE Obesity and Prediabetes (N = 2339) and SCALE Diabetes (N = 584) trials.
Summary · context
Dose proportionality of liraglutide in obese subjects was investigated using data from a phase II dose-finding study (N = 331).
Report a problemFND-2719327009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 19 Jan 2018

CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 29 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.